ArticleAnnals of surgical oncology2026
Risk Factors for Recurrence of Non-Small-Cell Lung Cancer After Anatomical Segmentectomy.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to identify prognostic factors associated with recurrence after anatomical segmentectomy in patients with clinical stage IA1 and IA2 non-small-cell lung cancer (NSCLC).
methodsAll patients who underwent anatomical segmentectomy for clinical stage IA1 and IA2 NSCLC between January 2018 and January 2020 were included. Recurrence was histologically confirmed, with recurrent tumors presenting histopathological features identical to the primary lung cancer. Baseline clinical and pathological characteristics of patients with and without recurrence were compared using inferential statistical methods. Kaplan-Meier and Cox regression analyses evaluated significant predictors of recurrence over time.
resultsA total of 180 patients were retrospectively analyzed (mean age 70.4 ± 7.5 years; 63.9% males; mean follow-up 3.1 ± 0.9 years). Recurrence occurred in 18 patients (10%). Logistic regression analysis indicated that recurrence was 5.1 times more prevalent in patients with tumor size ≥ 1.5 cm than in those with tumor size < 1.5 cm (odds ratio [OR] 5.1; 95% confidence interval [CI] 1.4-18.4, p = 0.01) and 2.9 times more prevalent in patients with pathological upstaging than in those without (OR 2.9; 95% CI 1.0-8.2, p = 0.04). Kaplan-Meier analysis revealed significant differences in recurrence-free estimates between patients with solid tumors ≥ 1.5 cm and those < 1.5 cm (p < 0.01) and between those with and without pathological upstaging (p = 0.05).
conclusionsRecurrence after anatomical segmentectomy for stage IA1 and IA2 NSCLC is significantly influenced by tumor size and pathological upstaging, underscoring the importance of tailored surgical strategies and meticulous pathological assessment to optimize long-term outcomes and reduce recurrence risk.
Indexed as
Identifiers
41379260What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.